FDA guidance now expects manufacturers to not only design secure products but also manage risk throughout the device lifecycle. Yet, between 2013 and 2018, only a small fraction of the NIST-CSF cybersecurity subcategories were referenced in medical device vulnerability disclosures. The findings highlight a critical gap: while 72% of the FDA’s recommendations address process interventions, 28% require product solutions — areas where software-based tools like Medcrypt can have the most direct impact.
This whitepaper helps medical device leaders understand:
- Where current postmarket cybersecurity efforts fall short
- How FDA and NIST-CSF frameworks intersect
- Which vulnerabilities can be technically mitigated through embedded security solutions